Lumos Pharma has raised a total of $48M across 9 funding rounds. Topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in PGHD met all primary and secondary endpoints (October 2025), positioning the company to advance toward regulatory submissions. The company is led by a management team with longstanding experience in rare disease drug development.
Cyborg Score Rationale
Lumos Pharma demonstrates solid fundamentals as a clinical-stage rare disease biotech with positive Phase 2 trial data, experienced management, and significant capital raised ($48M). However, as a pre-commercial entity with unproven regulatory pathway and limited revenue ($2.05M in 2023), execution risk remains material.
Top Insights
LUM-201 achieved all primary and secondary endpoints in Phase 2 trials (October 2025), substantially de-risking the clinical program
Lead candidate targets large addressable market ($4.5B global GH market) with significant clinical advantage (oral vs. injectable)
$48M raised to date with experienced rare disease management team positions the company for Phase 3 initiation
Orphan Drug Designation in US and EU provides regulatory incentives and accelerated pathways for rare disease indication
Named Competitors
Alnylam — RNA interference therapeutics for rare diseases
BridgeBio — Precision genetic medicine for rare diseases
Alexion — Rare disease and cell therapy leader
Recent Developments
(October 2025) Topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials met all primary and secondary endpoints
(April 2026) Lumos Pharma operating with 47 employees as a Series B-stage private company
Open the full interactive Lumos Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.